Curadev Therapeutics

Curadev is a privately held drug discovery and development company focused on creating small molecule therapeutics for oncology, inflammation, and neurodegeneration. The company utilizes a proprietary discovery platform to identify and optimize lead compounds against challenging biological targets such as STING, HPK1, and IDO/TDO. Curadev has established significant research and licensing collaborations with major pharmaceutical companies including Roche, Bayer, and Takeda. Their lead internal program, CRD5500, is a STING agonist currently being evaluated in clinical trials for the treatment of advanced solid tumors. Headquartered in India with operations in the United States, Curadev combines deep expertise in medicinal chemistry and biology to advance its diverse pipeline.